Orphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C in the Journal of Inherited Metabolic Disease

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice